Praxis Precision Medicines Inc

NASDAQ:PRAX   3:59:58 PM EDT
21.33
+1.35 (+6.76%)
Earnings Announcements

Praxis Precision Medicines Reports Prax-114 Perimenopausal Depression (Pmd) Phase 2A Proof-Of-Concept Trial Results

Published: 08/16/2021 13:00 GMT
Praxis Precision Medicines Inc (PRAX) - Praxis Precision Medicines Reports Prax-114 Perimenopausal Depression (pmd) Phase 2a Proof-of-concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women With Menopausal and Mood Symptoms.
Praxis Precision Medicines Inc - Prax-114 Was Well Tolerated in Phase 2a Pmd Study With No Change in Overall Safety Profile.
Praxis Precision Medicines Inc - Prax-114 Showed Rapid and Marked Improvements in Menopausal and Mood Symptoms in Phase 2a Pmd Study.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.93

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.02

More details on our Analysts Page.